YU Cell Culture Technologies Transferred to Businesses N
No.89148- Writer pr
- Date : 2019.05.10 10:40
- Views : 8053
Technology developed by YU Department of Medical Biotechnology Professor Choi In-ho (Cell Culture Research Center Chief) signs agreement for technology transfer with Ecell
Commercialization expected to expand to the cell culture market and cosmeceutical market
Technology transfer fee ‘1 billion KRW + 2% of sales’
[April 23, 2019]
Commercialization expected to expand to the cell culture market and cosmeceutical market
Technology transfer fee ‘1 billion KRW + 2% of sales’
[April 23, 2019]
<From left to right, YU Department of Medical Biotechnology Professor Choi In-ho, Industry-Academic Cooperation Cooperation Team Leader Park Yong-wan, President Sur Gil-soo, Ecell CEO Kim Doo-hyun)
At 1:30 p.m. on the 22nd (Mon), YU signed a technology transfer agreement with Ecell (CEO Kim Doo-hyun). The technologies that were transferred are ‘New Peptide FNIN2 that Promotes Cell Proliferation and Splitting and Its Use) and ’New Peptide FNIN3 that Promotes Cell Adhesion, Proliferation and Splitting and Its Use’ developed by YU Department of Medical Biotechnology Professor Choi In-ho. The technologies subject to the technology transfer can be used in various fields such as the stem cell culture solution (medium) market, cosmeceutical market including cosmetic products having stem cell medium, and the stem cell treatment market, and therefore, it is expected to create a new market together with the rise of the anti-aging industry for the aging society.
Technologies for developing new drugs and materials using advanced IT technologies in the bio sector have recently been on a stark rise mainly in advanced countries. Professor Choi’s research team successfully developed peptides specialized in stem cell treatment using ‘Insilico’ analysis technologies used for bio phenomena and pharmaceutical product research through big data information and computer simulation on protein structures that exist in the cell barrier. It is expected that through this, production efficiency of bio pharmaceutical products specialized for stem cell treatment substances will increase.
YU signed a 1 billion KRW contract for technology transfer fees of this technology and it will also receive 2% of all sales from the business of the company for three years.
Ecell is a company that manufactures products related to disposal cell culture processes and with this technology transfer, it is planning to transfer its head office or split its company and open a new location in Uiseong-gun, Gyeongsangbuk-do.
YU President Sur Gil-soo said, “Technologies and research capacities of YU are being sought after by many companies.” He added, “YU will take the initiative to create new growth engines for not only YU and businesses, but also for the local community through continued industry-academic cooperation.”
YU Industry-Academic Cooperation Team Leader Park Yong-wan said, “As it takes a long time for bio technologies to become commercialized, the industry-academic team will do its best to improve the possibilities to commercialize technologies through flexible ties between the industry-academic cooperation team and businesses.”
Ecell teamed up with the YU Technology Transfer Commercialization Center for the inter-collegiate convergence commercialization project (supervised by Chonnam National University) of the Ministry of Education’s (National Research Foundation) Beyond Research Innovation & Development for Good Enterprises + (BRIDGE+) to receive funding for commercialization and has been pursuing technology commercialization.
This technology is the result of research on Gyeongsangbuk-do’s ‘4th Industrial Revolution Core Technology Development Project’ (overseen by the department of science policy, 3 years, 800 million KRW) and under the leadership of YU Department of Medical Biotechnology Professor Choi In-ho (Cell Culture Research Center Chief), it was joined by College of Pharmacy Professor Jung Ji-heon and College of Medicine Professor Doh Gyeong-ho. Professor Choi’s research team has focused on developing treatment related to muscles and commercializing cell culturing technologies through research on muscle stem cells for over 10 years.